Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
المؤلفون المشاركون
Han, Tianzhao
Rong, Gong
Quan, Dayong
Shu, Ying
Liang, Zhu
She, Ninglan
Liu, Manli
Yang, Bing
Cheng, Gong
Lv, Yongman
Stern, Leonard
المصدر
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-11، 11ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-12-27
دولة النشر
مصر
عدد الصفحات
11
التخصصات الرئيسية
الملخص EN
Previous studies have demonstrated the safety and efficacy of using Paricalcitol for the treatment of secondary hyperparathyroidism (SHPT) in patients on dialysis.
The aim of the current meta-analysis was to assess the safety and efficacy of Paricalcitol for the management of SHPT in patients with chronic kidney disease (CKD) not yet on dialysis.
A secondary aim was to determine if sufficient data was available to assess the effect of Paricalcitol for the management of proteinuria.
Methods.
A meta-analysis was conducted using the Cochrane Collaboration’s RevMan 4.2 software.
Results.
Paricalcitol is effective in lowering PTH in patients with CKD not yet on dialysis and is also effective in lowering proteinuria in diabetic CKD patients.
However, we uncovered a safety signal identifying an elevated calcium phosphate product and a trend towards the development of hypercalcemia.
A phosphate elevation was not demonstrated because the target used in the clinical studies was a P>5.5 mg/dl, a value appropriate for dialysis patients and not CKD patients.
Conclusion.
Although Paricalcitol is effective in lowering PTH, we advise caution in the use of any active Vitamin D analogues in patients with CKD because of the potential risk of exacerbating vascular calcification.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Han, Tianzhao& Rong, Gong& Quan, Dayong& Shu, Ying& Liang, Zhu& She, Ninglan…[et al.]. 2012. Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease. BioMed Research International،Vol. 2013, no. 2013, pp.1-11.
https://search.emarefa.net/detail/BIM-1004019
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Han, Tianzhao…[et al.]. Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease. BioMed Research International No. 2013 (2013), pp.1-11.
https://search.emarefa.net/detail/BIM-1004019
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Han, Tianzhao& Rong, Gong& Quan, Dayong& Shu, Ying& Liang, Zhu& She, Ninglan…[et al.]. Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease. BioMed Research International. 2012. Vol. 2013, no. 2013, pp.1-11.
https://search.emarefa.net/detail/BIM-1004019
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1004019
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر